Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 9:52 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 696 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Hepatitis, Chronic Clear all

Conditions: Hepatitis B
Interventions: GSK3228836, Placebo, Nucleos(t)ide therapy; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 457 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 8
States / cities: Los Angeles, California • Miami, Florida • Decatur, Georgia + 4 more

Conditions: Hepatitis B, Chronic
Interventions: Blood Testing, Percutaneous Liver Biopsy, Lamivudine Therapy; Procedure
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Chronic Hepatitis B
Interventions: TDF, ADV, TDF placebo, ADV placebo, FTC/TDF; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 69 Years
Enrollment: 266 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2016
U.S. locations: 20
States / cities: Orange, California • Pasadena, California • San Diego, California + 14 more

Conditions: Hepatitis C Virus (HCV)
Interventions: Glecaprevir/pibrentasvir; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 11
States / cities: La Jolla, California • Pasadena, California • Tampa, Florida + 7 more

Conditions: Healthy, Hepatitis C, Chronic
Interventions: TG-2349, placebo; Drug
Lead sponsor: TaiGen Biotechnology Co., Ltd.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 135 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Cypress, California

Conditions: Hepatitis C, Chronic, Heart Failure, Pulmonary Disease, Chronic Obstructive, Lung Diseases, Interstitial
Interventions: Sofosbuvir/ledipasvir fixed dose combination(SOF/LDV FDC); Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 4
States / cities: Detroit, Michigan • New York, New York • Durham, North Carolina + 1 more

Conditions: Chronic Hepatitis C Infection
Interventions: Fuzheng Huayu, Placebo; Drug
Lead sponsor: Tarek Hassanein; Individual
Eligibility: 18 Years to 70 Years
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 8
States / cities: Coronado, California • Palo Alto, California • Pasadena, California + 5 more

Conditions: Chronic Hepatitis B
Interventions: NVR 3-778, Placebo for NVR 3-778, Pegasys; Drug
Lead sponsor: Novira Therapeutics, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 4
States / cities: Costa Mesa, California • Pasadena, California • San Diego, California + 1 more

Conditions: Chronic Hepatitis C Infection
Interventions: ABT-267, ABT-450, ABT-333, Ritonavir, Ribavirin; Drug
Lead sponsor: AbbVie (prior sponsor, Abbott); Industry
Eligibility: 18 Years to 70 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 4
States / cities: Bakersfield, California • Orlando, Florida • Annapolis, Maryland + 1 more

Conditions: Hepatitis C
Interventions: Daclatasvir, Sofosbuvir; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 173 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 30
States / cities: La Jolla, California • Los Angeles, California • Pasadena, California + 23 more

Conditions: Hepatitis B, Human Immunodeficiency Virus, Hepatitis C, Chronic
Interventions: maraviroc, etravirine; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 16 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 15
States / cities: Clearwater, Florida • Orlando, Florida • Safety Harbor, Florida + 10 more

Conditions: Hepatitis B
Interventions: TDF, FTC/TDF, TDF Placebo, FTC/TDF Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 280 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 3
States / cities: Bradenton, Florida • Flushing, New York • Philadelphia, Pennsylvania

Conditions: Hepatitis C, Medication Adherence
Interventions: Patient Navigation, modified Directly Observed Therapy; Behavioral
Lead sponsor: Prisma Health-Upstate; Other
Eligibility: 18 Years to 70 Years
Enrollment: 755 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Hepatitis C
Interventions: VCH-222 or matching placebo, peginterferon alfa-2a, ribavirin; Drug · Biological
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 4
States / cities: Marietta, Georgia • Detroit, Michigan • Dallas, Texas + 1 more

Conditions: Chronic Hepatitis C
Interventions: Omega DUROS device; Drug
Lead sponsor: Intarcia Therapeutics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 7
States / cities: Los Angeles, California • San Francisco, California • St Louis, Missouri + 4 more

Conditions: Hepatitis C, Liver Disease
Interventions: Alisporivir, Ribavirin; Drug
Lead sponsor: Debiopharm International SA; Industry
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 11
States / cities: Bakersfield, California • Lancaster, California • San Diego, California + 6 more

Conditions: Hepatitis C
Interventions: Omega-3 Fatty Acids, Placebo comparator; Dietary Supplement · Drug
Lead sponsor: University of Missouri, Kansas City; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 2
States / cities: Kansas City, Missouri

Conditions: Chronic Hepatitis C Virus
Interventions: LDV/SOF, RBV; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 647 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 52
States / cities: Birmingham, Alabama • La Jolla, California • Los Angeles, California + 49 more

Conditions: Liver Cancer
Interventions: Bevacizumab, Atezolizumab, Sofosbuvir, Velpatasvir, Voxilaprevir, Ribavirin; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Hepatitis C Virus Infection, Infection, Herpesvirus 2, Human
Interventions: Valacyclovir; Drug
Lead sponsor: G.V. (Sonny) Montgomery VA Medical Center; Federal
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Jackson, Mississippi

Conditions: ESRD
Interventions: Glecaprevir/pibrentasvir; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 99 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Hepatitis C, Chronic
Interventions: RO5024048, Ribavirin [Copegus], peginterferon alfa-2a [Pegasys]; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 19
States / cities: La Jolla, California • Bradenton, Florida • Atlanta, Georgia + 14 more

Conditions: Hepatitis C, Cirrhosis, Portal Hypertension, With or Without Liver Decompensation
Interventions: SOF, RBV; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 4
States / cities: Aurora, Colorado • Boston, Massachusetts • Rochester, Minnesota + 1 more

Conditions: Hepatitis, Hepatitis B, Chronic, Cirrhosis
Interventions: Telbivudine, Lamivudine, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 16 Years to 70 Years
Enrollment: 232 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 8
States / cities: Phoenix, Arizona • Los Angeles, California • Denver, Colorado + 5 more

Search by objective public record fields.

A Study of GSK3228836 in Participants With Chronic Hepatitis B (CHB)

Long-Term Lamivudine Therapy for Chronic Hepatitis B

A Study to Compare Tenofovir Disoproxil Fumarate Versus Adefovir Dipivoxil for the Treatment of HBeAg-Positive Chronic Hepatitis B

A Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus Genotype 1 - 6 Infection and Renal Impairment

A Study to Evaluate the Safety, Tolerability, and PK in Healthy Volunteers and HCV Genotype 1 Infected Patients

Hepatitis C Virus(HCV) Heart and Lung Study

Assess the Antifibrotic Activity of Fuzheng Huayu in Chronic Hepatitis C Patients With Hepatic Fibrosis

Dose-Ranging Study to Assess the Safety, PK and Initial Antiviral Efficacy of NVR 3-778 in Chronic HBV Patients

Study to Assess the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of ABT-267 in HCV Infected Subjects

Phase III Daclatasvir and Sofosbuvir for Genotype 3 Chronic HCV

Maraviroc Versus Etravirine In Combination With Antiretroviral Therapy In Drug Experienced HIV And Hepatitis Co-Infected Patients

Tenofovir Disoproxil Fumarate (Tenofovir DF) Versus Emtricitabine/Tenofovir DF in Subjects Resistant to Lamivudine

Patient-Centered Models of HCV Care for People Who Inject Drugs

Pharmacokinetics of Multiple Ascending Doses of VCH-222 in Subjects With Chronic Hepatitis C Infection

Phase 1b Study of Omega DUROS® in Patients With Chronic Hepatitis C Who Relapsed After Prior Treatment

Alisporivir With RBV in Chronic Hepatitis C Genotype 2 and 3 Participants for Whom Interferon is Not an Option

Use of Omega-3 Fatty Acids (Fish Oil) in Patients With Chronic Hepatitis C Infection

Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin for the Treatment of HCV (ION-3)

Improving Response to Immunotherapy in Patients With Advanced Hepatocellular Carcinoma and Chronic Hepatitis C Virus Infection With Direct-Acting Antiviral Therapy

Herpes Simplex Type 2 Co-infection in Veterans With Chronic Hepatitis C

A Single-center Pilot Study Evaluating a Preemptive Short Course of Glecaprevir/Pibrentasvir in Hepatitis C Positive to Negative Kidney Transplantation

A Study of RO5024048 in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 1 or 4

Sofosbuvir and Ribavirin in Patients With Chronic HCV With Cirrhosis and Portal Hypertension With or Without Liver Decompensation

Telbivudine Versus Lamivudine in Adults With Decompensated Chronic Hepatitis B and Evidence of Cirrhosis